Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis

BACKGROUND: TP53 mutations, which are present in 5% to 10% of patients with acute myeloid leukemia (AML), are associated with treatment resistance and poor outcomes. First-line therapies for TP53-mutated (TP53m) AML consist of intensive chemotherapy (IC), hypomethylating agents (HMA), or venetoclax...

Descripción completa

Detalles Bibliográficos
Autores principales: Daver, Naval G., Iqbal, Shahed, Renard, Camille, Chan, Rebecca J., Hasegawa, Ken, Hu, Hao, Tse, Preston, Yan, Jiajun, Zoratti, Michael J., Xie, Feng, Ramsingh, Giridharan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990239/
https://www.ncbi.nlm.nih.gov/pubmed/36879351
http://dx.doi.org/10.1186/s13045-023-01417-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990239/
https://www.ncbi.nlm.nih.gov/pubmed/36879351
http://dx.doi.org/10.1186/s13045-023-01417-5

Ejemplares similares